Month: April 2022

Proterra’s ZX5 electric transit bus The 40-foot Proterra ZX5 Max selected by Pace features 675 kilowatt hours (kWh) of energy storage, the most onboard energy storage available in an electric transit bus on the road in North America today.BURLINGAME, Calif. and ARLINGTON HEIGHTS, Ill., April 05, 2022 (GLOBE NEWSWIRE) — Proterra Inc (NASDAQ: PTRA), a leading innovator in commercial vehicle electrification technology, and Pace Suburban Bus today announced a landmark fleet electrification project with the agency awarding a $26.5 million dollar contract to Proterra to acquire 20 Proterra ZX5 Max electric transit buses, featuring more than 13 megawatt hours of battery storage energy, and two Proterra megawatt-scale fleet chargers. The procurement represents Pace’s first order of battery-electric buses as the agency seeks to...

Mark K. Patterson Appointed Senior Vice President Marjorie Hargrave, President and CFO, is Departing on April 22, 2022 LONGMONT, Colo., April 05, 2022 (GLOBE NEWSWIRE) — Enservco Corporation (NYSE American: ENSV), a diversified national provider of specialized well-site services to the domestic onshore conventional and unconventional oil and gas industries, today announced that Mark K. Patterson has joined the Company as Senior Vice President. Patterson is an accomplished senior executive with extensive experience in financial and strategic planning, operations, logistics, capital markets, and M&A. He is a growth-oriented manager with a track record of leading and executing transformative business and financial strategies with private and public companies ranging from start-ups to multi-billion-dollar enterprises. Patterson...

– Total Product Revenues Expected in the Range of $450.0 million to $465.0 million – – Adjusted Operating Expenses Expected in the Range of $130.0 million to $140.0 million – – Adjusted EBITDA Expected in the Range of $235.0 million to $250.0 million – STOUGHTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced updated financial guidance for the full year 2022 to include the expected impact of the BioDelivery Sciences International Inc. (“BDSI”) acquisition. As previously announced, the Company completed the acquisition of BDSI on March 22, 2022. “2022 is a pivotal year, as we take actions to advance our mission of building a leading, diversified specialty pharmaceutical company committed to improving the lives of people...

TAMPA, Fla., April 05, 2022 (GLOBE NEWSWIRE) — HCI Group, Inc. (NYSE:HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, will hold its Annual Meeting of Shareholders on Thursday, June 2, 2022, at 3:00 p.m. Eastern time in the 1st Floor Auditorium of our headquarters at 3802 Coconut Palm Drive, Tampa, Florida. Shareholders of record at the close of business on Tuesday, April 12, 2022, will be entitled to vote and attend the meeting. Items of business will include the following proposals:To elect Class B Directors To ratify the appointment of external auditors To approve, on an advisory basis, the compensation of the named executive officersShareholders will also consider such other business as may properly come before the Annual Meeting and any adjournments...

LAS VEGAS, April 05, 2022 (GLOBE NEWSWIRE) — CLS Holdings USA, Inc. (OTCQB:CLSH) (CSE:CLSH), the ”Company” or ”CLS”, a diversified cannabis company operating as Cannabis Life Sciences, will host a webcast on Thursday, April 14, 2022 at 5 p.m. ET to discuss the Company’s financial highlights for its third quarter of fiscal year 2022.   Event: CLS Holdings USA, Inc. Q3 FY 2022 Financial Results WebcastDate: Thursday, April 14, 2022Time: 5:00 p.m. Eastern TimeWebcast: https://onlinexperiences.com/Launch/QReg/ShowUUID=E795A5B4-8436-4A51-BD49-1BE65CB39778&LangLocaleID=1033&GroupID=OnyxFor interested individuals unable to join the webcast, a replay of the webcast will be available on the CLS Holdings USA, Inc., website and can be accessed by visiting https://www.clsholdingsinc.com/news-media/press-releases About...

NEW YORK, April 05, 2022 (GLOBE NEWSWIRE) — Apollo Global Management, Inc. (NYSE: APO) (together with its consolidated subsidiaries, “Apollo”) plans to release financial results for the first quarter 2022 on Thursday, May 5, 2022, before the opening of trading on the New York Stock Exchange. Management will review Apollo’s financial results at 8:30 am ET via audio webcast, which will be accessible at https://www.apollo.com/stockholders/events-and-presentations. For those unable to listen to the live broadcast, there will be a replay of the webcast available at the same link one hour after the event. Apollo distributes its earnings releases via its website and email distribution lists. Those interested in receiving firm updates by email can sign up for them here. About ApolloApollo is a global, high-growth alternative asset manager....

XMT-1660 demonstrates robust activity in preclinical models of breast cancer XMT-2056 demonstrates robust activity as monotherapy, in combination with standard of care therapies and in both HER2-high and HER2-low expressing preclinical models Both programs on track to initiate Phase 1 clinical trials in mid-2022 CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present three posters highlighting data for XMT-1660, XMT-2056, and the Immunosynthen ADC platform at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 to be held in New Orleans, Louisiana...

LONDON, April 05, 2022 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that management will be taking part in the following conferences in April.Accelerating Bio-Innovation 2022 in Cambridge, UK on Tuesday, April 5, 2022 at 2:25pm UK. Iraj Ali, CEO, will participate in a panel entitled, “Next-Gen Immuno Oncology.” 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 8:00am ET / 1:00pm UK. Iraj Ali, CEO, will give a corporate presentation. 14th Kempen Life Sciences Conference in Amsterdam, Netherlands on Wednesday, April 20, 2022. Iraj Ali, CEO, and Robert Coutts, CFO, will participate in one-on-one and small group investor meetings. Chardan’s 6th Annual Virtual Genetic...

MINNEAPOLIS, April 05, 2022 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the first quarter 2022 after the close of trading on Tuesday, May 3. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.Tuesday, May 3rd @ 5:00 p.m. Eastern Time:Domestic:  (800) 344-0786International:  (209) 905-5969Conference ID: 5029338Webcast: https://edge.media-server.com/mmc/p/inp4vfpuAbout Inspire Medical SystemsInspire is a medical technology company focused on the...

–Seasoned physician, scientist and life science executive brings expertise in clinical research and development across product life cycle– –Key appointment as Humacyte advances HAV through multiple late-stage clinical trials in initial vascular applications– DURHAM, N.C., April 05, 2022 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Shamik J. Parikh, M.D., as Chief Medical Officer. In this role, Dr. Parikh will lead the company’s global clinical development strategy, including oversight of the preclinical and clinical development, clinical operations, and medical affairs functions. “We are pleased to welcome Shamik to Humacyte’s leadership...